WilliamCCromwellMDFAHA, FNLA

PubMed

• 29 citations
  Precision screening for familial hypercholesterolaemia: a machine learning study applied to electronic health encounter data.
  Kelly D. Myers, Joshua W. Knowles, David Staszak, Michael D. Shapiro, William James Howard, Mrinal Yadava, David Zuzick, Latoya Williamson, Nigam H. Shah, Juan M. Band...> ;The Lancet. Digital Health. 2019 Dec 1
• 51 citations
  Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding
  Allan D. Sniderman, Patrick Couture, Seth S. Martin, Jacqueline DeGraaf, Patrick R. Lawler, William C. Cromwell, John T. Wilkins, George Thanassoulis> ;Journal of Lipid Research. 2018 Jul 1
• 6 citations
  Cost Effectiveness of Achieving Targets of Low-Density Lipoprotein Particle Number Versus Low-Density Lipoprotein Cholesterol Level.
  Michael Grabner, Deborah A. Winegar, Rajeshwari S. Punekar, Ralph Quimbo, Mark J. Cziraky, William C. Cromwell> ;The American Journal of Cardiology. 2017 Feb 1
• 34 citations
  Discordance of Low-Density Lipoprotein and High-Density Lipoprotein Cholesterol Particle Versus Cholesterol Concentration for the Prediction of Cardiovascular Disease ...
  David M. Tehrani, Yanglu Zhao, Michael J. Blaha, Samia Mora, Rachel H. Mackey, Erin D. Michos, Matthew J. Budoff, William C. Cromwell, James D. Otvos, Paul D. Rosenbli...> ;The American Journal of Cardiology. 2016 Jun 15
• 22 citations
  Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia
  Raul D. Santos, Frederick J. Raal, Joanne M. Donovan, William C. Cromwell> ;Journal of Clinical Lipidology. 2015 Mar 1
• 29 citations
  Nematicidal Effects of Silver Nanoparticles on Root-knot Nematode in Bermudagrass.
  William Cromwell, Joopil Yang, James L. Starr, Young-Ki Jo> ;Journal of Nematology. 2014 Sep 15
• 171 citations
  Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a rando...
  Gregory S. Thomas, William C. Cromwell, Shariq Ali, Wai Chin, JoAnn Flaim, Michael H. Davidson> ;Journal of the American College of Cardiology. 2013 Dec 10
• 33 citations
  Site-Directed Mutations in the Lanthipeptide Mutacin 1140
  Shaorong Chen, Shawanda Wilson-Stanford, William Cromwell, Jeffrey D. Hillman, Adam Guerrero, Charlotte A. Allen, Joseph A. Sorg, Leif Smith> ;Applied and Environmental Microbiology. 2013 Jul 1
• 2 citations
  Clinical utility of low-density lipoprotein particles and apolipoprotein B in patients with cardiovascular risk.
  Jennifer L Ennis, William C. Cromwell> ;The Journal of Family Practice. 2013 Jul 1
• 185 citations
  Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists.
  Michael H. Davidson, Christie M. Ballantyne, Terry A. Jacobson, Vera Bittner, Lynne T. Braun, Alan S. Brown, W. Virgil Brown, William C. Cromwell, Ronald B. Goldberg, ...> ;Journal of Clinical Lipidology. 2011 Sep 1
• Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel ...
  Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, Daniels SR, Gidding SS, de Ferranti SD, Ito MK, McGowan MP, Moriarty PM, Cromwell WC, Ross JL, ...> ;J Clin Lipidol. 2011-06-01
• 23 citations
  Future issues, public policy, and public awareness of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hype...
  Anne C. Goldberg, Jennifer G. Robinson, William C. Cromwell, Joyce L. Ross, Paul Ziajka> ;Journal of Clinical Lipidology. 2011 Jun 1
• 332 citations
  Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients
  Anne C. Goldberg, Paul N. Hopkins, Peter P. Toth, Christie M. Ballantyne, Daniel J. Rader, Jennifer G. Robinson, Stephen R. Daniels, Samuel S. Gidding, Sarah D. de Fer...> ;Journal of Clinical Lipidology. 2011 May 1
• 640 citations
  Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a rando...
  Frederick J. Raal, Raul D. Santos, Dirk J. Blom, A. David Marais, Min-Ji Charng, William C. Cromwell, Robin H. Lachmann, Daniel Gaudet, Ju L. Tan, Scott Chasan-Taber, ...> ;Lancet. 2010 Mar 20
• 31 citations
  Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease.
  William C. Cromwell, Thomas A. Barringer> ;Current Cardiology Reports. 2009 Nov 29
• 1 citations
  Arterial age as a function of coronary artery calcium.
  Thomas A. Barringer, William C. Cromwell> ;The American Journal of Cardiology. 2009 May 1
• 289 citations
  LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL management
  William C. Cromwell, James D. Otvos, Michelle J. Keyes, Michael J. Pencina, Lisa M. Sullivan, Ramachandran S. Vasan, Peter W.F. Wilson, Ralph B. D'Agostino> ;Journal of Clinical Lipidology. 2007 Dec 1
• 6 citations
  High-density lipoprotein associations with coronary heart disease: Does measurement of cholesterol content give the best result?
  William C. Cromwell> ;Journal of Clinical Lipidology. 2007 Mar 1
• 50 citations
  Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl.
  William C. Cromwell, James D. Otvos> ;The American Journal of Cardiology. 2006 Dec 15
• 555 citations
  Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy.
  Elias J. Jeyarajah, William C. Cromwell, James D. Otvos> ;Clinics in Laboratory Medicine. 2006 Dec 1
• 119 citations
  Low-density lipoprotein particle number and risk for cardiovascular disease.
  William C. Cromwell, James D. Otvos> ;Current Atherosclerosis Reports. 2004 Sep 1
• 187 citations
  Measurement issues related to lipoprotein heterogeneity.
  James D. Otvos, Elias J. Jeyarajah, William C. Cromwell> ;The American Journal of Cardiology. 2002 Oct 17
• 21 citations
  Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia.
  Michael Miller, Christina Dolinar, William C. Cromwell, James D. Otvos> ;The American Journal of Cardiology. 2001 Jan 15
• 18 citations
  Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors.
  William C. Cromwell, Paul Ziajka> ;The American Journal of Cardiology. 2000 Nov 15
• Join now to see all

Journal Articles

• Mipomersen Preferentially Reduces Small LDL Particle Number in Patients with Hypercholesterolemia  
  Santos RD, Raal FJ, Donovan JM, Cromwell WC, Journal of Clinical Lipidology, 1/1/2015
• Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients with Severe Hypercholesterolemia at High Cardiovascular Risk: A Rando...  
  Thomas GS, Cromwell WC, Ali S, Chin W, Flaim JD, Davidson M., Journal of American College of Cardiology, 1/1/2013
• Clinical Utility of Low-density Lipoprotein Particles and Apolipoprotein B in Patients with Cardiovascular Risk  
  Ennis JL, Cromwell WC, The Journal of Family Practice, 1/1/2013
• Safety and Efficacy of Mipomersen Administered as Add-on Therapy in Patients with Hypercholesterolemia and High Cardiovascular Risk  
  Cromwell WC, Thomas GS, Boltje I, Chin W, Davidson M, Journal of Clinical Lipidology, 1/1/2012
• Familial Hypercholesterolemia: Screening, Diagnosis and Management of Pediatric and Adult Patients: Clinical Guidance from the National Lipid Association Expert Panel ...  
  Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, Daniels SR, Gidding SS, de Ferranti SD, Ito MK, McGowan MP, Moriarty PM, Cromwell WC, Ross JL, ..., Journal of Clinical Lipidology, 1/1/2011
• Future Issues, Public Policy, and Public Awareness of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hype...  
  Goldberg AC, Robinson JG, Cromwell WC, Ross JL, Ziajka PE, Journal of Clinical Lipidology, 1/1/2011
• Clinical Utility of Inflammatory Markers and Advanced Lipoprotein Testing: Advice from an Expert Panel of Lipid Specialists  
  Davidson MH, Ballantyne CM, Jacobson TA, Bittner VA, Braun LT, Brown AS, Brown WV, Cromwell WC, Goldberg RB, McKenney JM, Remaley AT, Sniderman AD, Toth PP, Tsimikas S..., Journal of Clinical Lipidology, 1/1/2011
• Mipomersen, an Apolipoprotein B Synthesis Inhibitor, for Lowering of Ldl Cholesterol Concentrations in Patients with Homozygous Familial Hypercholesterolaemia: A Rando...  
  Raal FJ, Santos RD, Blom DJ, Marais AD, Charng M-J, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim JD, Crooke ST, The Lancet, 1/1/2010
• Ldl Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for Ldl Management  
  Cromwell WC, Otvos JD, Keyes MJ, Pencina MJ, Sullivan L, Vasan RS, Wilson PWF, D'Agostino RB, Journal of Clinical Lipidology, 1/1/2007
• Hdl Associations with Coronary Heart Disease: Does Measurement of Cholesterol Content Give the Best Result?  
  Cromwell WC, Journal of Clinical Lipidology, 1/1/2007
• Lipoprotein Particle Analysis by Nuclear Magnetic Resonance Spectroscopy  
  Jeyarajah EJ, Cromwell WC, Otvos JD, Clin Lab Med., 1/1/2006
• Cyclodextrin-adamantanecarboxylate Inclusion Complexes: Studies of the Variation in Cavity Size  
  Cromwell WC, Bystrom K, Eftink MR, The Journal of Physical Chemistry, 1/1/1985
• Lipoprotein Disorders: Current Guidelines and Practical Solutions.  
  Cromwell W, Dayspring T, Richman M, International Guidelines Center
• Development of tachyphalaxis among patients taking HMG Co-A reductase inhibitors, Reply.  
  Cromwell W, Ziajka P, Am J Cardiol
• Cyclodextrin-adamantanecarboxylate inclusion complexes: studies of the variation in cavity size.  
  Cromwell WC, Bystrom K, Eftink MR, Journal of Physical Chemistry
• Join now to see all

Books/Book Chapters

• Lipid and Lipoprotein Disorders: Current Clinical Solutions 
  Cromwell W, Dayspring TInternational Guideline Center, Baltimore2012
• Familial Hypercholesterolemia: Current Dilemmas and Emerging Solutions in Screening and Treatment 
  Chapter: Treatment of Adults and Children with Familial Hypercholesterolemia and Evidence for Recommendations 
  Cromwell WEditors: Toth PP.2012
• Lipid and Lipoprotein Disorders: Current Clinical Solutions 
  Cromwell WC, Dayspring T, Richman MFInternational Guideline Center, Baltimore2009
• Clinical Challenges in Lipid Disorders 
  Chapter: Clinical Utilization of Advanced Lipid Testing. 
  Page 249.0 - 259.0Cromwell WCEditors: Toth PP, Sica DA.Clinical Publishing, Oxford2008
• Therapeutic Lipidology 
  Chapter: Clinical Utilization of Lipoprotein Subfractions 
  Page 321.0 - 348.0Cromwell WC, Otvos JDEditors: Davidson MH, Toth PP, Maki KC.Humana Press, Totowa2007
• Markers in Cardiology: A Case-oriented Approach 
  Chapter: Lipoprotein Subfraction Analysis Using Nuclear Magnetic Resonance Spectroscopy 
  Page 217.0 - 250.0Cromwell WC, Bays HE, Toth PPEditors: Adams JE, Apple F, Jaffe AS.Blackstone, London2007
• Establishing and Managing a Private Practice Lipid Clinic 
  Ziajka PE, Cromwell WCMosby-Wolfe, Philadelphia2000
• Lipid and Lipoprotein Disorders: Current Clinical Solutions. 
  Cromwell WC, Dayspring TInternational Guideline Center, BaltimoreEdition 2,
• Lipid and Lipoprotein Disorders: Current Clinical Solutions. 
  Cromwell WC, Dayspring T, Richman MFInternational Guidelines Center, BaltimoreEdition 1,
• Clinical Challenges in Lipid Disorders. 
  Chapter: Clinical utilization of advanced lipid testing 
  Page 249 - 259Cromwell WCEditors: Toth PP, Sica DA.Clinical Publishing, Oxford
• Therapeutic Lipidology. 
  Chapter: Clinical utilization of lipoprotein subfractions 
  Page 321 - 348Cromwell WC, Otvos JDEditors: Davidson MH, Toth PP, Maki KC.Humana Press, Totowa
• Markers in Cardiology: A Case-Oriented Approach. 
  Chapter: Lipoprotein subfraction analysis using nuclear magnetic resonance spectroscopy 
  Page 217 - 250Cromwell WC, Bays HE, Toth PPEditors: Adams JE, Apple F, Jaffe AS.Blackstone, London
• Establishing and Managing A Private Practice Lipid Clinic. 
  Ziajka PE, Cromwell WCMosby-Wolfe, PhiladelphiaEdition 2,
• Join now to see all

Abstracts/Posters

• Comparison of Cardiovascular Events between Patients Achieving Low-density Lipoprotein Particle Targets and Patients Achieving Low-density Lipoprotein Cholesterol Targ...
  Toth PP, Grabner M, Punekar R, Quimbo R, Cziraky M, Pourfarzib R, Cromwell W, Winegar D, Jacobson T., Journal of the American College of Cardiology., 1/1/2015
• Safety and Efficacy of Mipomersen Administered as Add-on Therapy in Patients with Hypercholesterolemia and High Cardiovascular Risk
  Cromwell WC, Thomas GS, Boltje I, Chin W, Davidson M., Journal of Clinical Lipidology, 1/1/2012
• Safety and Efficacy of Mipomersen Administered as Add- on Therapy in Patients with Hypercholesterolemia and High Cardiovascular Risk
  Cromwell WC, Thomas GS, Boltje I, Chin W, Davidson M, J Am Coll Cardiol, 1/1/2011
• Mipomersen, a First-in-class Apolipoprotein B Synthesis Inhibitor, Lowers Lipoprotein (A) In Patients with Homozygous Familial Hypercholesterolemia
  Cromwell WC, Santos RD, Blom DJ, Marais DA, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim J, Raal FJ, Charng M-J., Journal of Clinical Lipidology, 1/1/2010
• P431 Mipomersen, an apo B Synthesis Inhibitor, Preferentially Reduces Small LDL Particle Number and Increases LDL Particle Size in HoFH Patients
  Cromwell W, Santos R, Blom D, Marais AD, Charng MJ, Lachmann R, Gaudet D, Tan JL, Tribble D, Flaim J, Chasan-Taber S, Donovan J, Raal F, Atherosclerosis, 1/1/2010
• Mipomersen, An Apolipoprotein B Synthesis Inhibitor, Reduces Small LDL Particle Number and Increases LDL Particle Size in Patients with Heterozygous Familial Hyperchol...
  Cromwell W, Dufour R, Gagne C, Gaudet D, East C, Donovan JM, Chin W, Tribble DL, McGowan M, Circulation, 1/1/2010
• Mipomersen, a First-in-class Apo-b Synthesis Inhibitor, Lowers Ldlc in Patients with Homozygous Familial Hypercholesterolemia: Results of a Phase III Study
  Raal F, Santos R, Niu D-M, Lachmann RH, Gaudet D, Le Tan J, Cromwell WC, Marais D, Tribble DL, Flaim JD, Crooke ST., Circulation, 1/1/2009
• Mipomersen, a First-in-class Apolipoprotein B Synthesis Inhibitor, Lowers Lp(a) In Patients with Homozygous Familial Hypercholesterolemia and High Baseline Lp(a): Resu...
  Cromwell W, Santos R, Lachmann R, Gaudet D, Tan JL, Marais D, Raal F, Circulation, 1/1/2009
• LDL Particle Number is Highly Heterogeneous Among Patients With Type 2 Diabetes Mellitus At LDL Cholesterol Target Goal &lt;100 mg/dL
  Cromwell WC, Otvos JD., Circulation, 1/1/2005
• LDL Particles, but Not LDL Cholesterol, Are Highly Elevated in the Metabolic Syndrome - Results from the Framingham Offspring Study
  Otvos J, Cromwell W, Shalaurova I, Parise H, Wilson P, Robins S, D&#39;Agostino R, Schaefer E, Circulation, 1/1/2003
• Effects of Simvastatin and Atorvastatin on Total and Fractionated HDL Cholesterol
  Otvos J, Cromwell W, Alexander C, et al., XIIth International Symposium on Atherosclerosis, Atherosclerosis, Stockholm, Sweden, 1/1/2000
• Fluorescence Polarization Studies on the ATP Binding Site of Hexokinase
  Bhatnagar D, Cromwell WC, Roskoski R, Fed Proc, 1/1/1985
• Thermodynamic and Fluorescence Studies of the pH Dependence of the Binding of NAD+ to Liver Alcohol Dehydrogenase
  Eftink MR, Riggins M, Cromwell W, Biophys J, 1/1/1983
• Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a rando...
  Raal FJ, Santos RD, Blom DJ, Marais AD, Charng M-J, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan- Taber S, Tribble DL, Flaim JD, Crooke ST, The Lancet
• Safety and Efficacy of Mipomersen Administered as Add- on Therapy in Patients with Hypercholesterolemia and High Cardiovascular Risk.
  Cromwell WC, Thomas GS, Boltje I, Chin W, Davidson M, J Clin Lipidology
• Safety and Efficacy of Mipomersen Administered as Add- on Therapy in Patients with Hypercholesterolemia and High Cardiovascular Risk.
  Cromwell WC, Thomas GS, Boltje I, Chin W, Davidson M, J Am Coll Cardiol
• P431 Mipomersen, an apo B Synthesis Inhibitor, Preferentially Reduces Small LDL Particle Number and Increases LDL Particle Size in HoFH Patients.
  Cromwell W, Santos R, Blom D, Marais AD, Charng MJ, Lachmann R, Gaudet D, Tan JL, Tribble D, Flaim J, Chasan-Taber S, Donovan J, Raal F, Atherosclerosis. Supplements
• Mipomersen, a First-in-Class Apo-B Synthesis Inhibitor, Lowers LDL-C in Patients With Homozygous Familial Hypercholesterolemia: Results of a Phase III Study.
  Raal F, Santos R, Niu D-M, Lachmann RH, Gaudet D, Le Tan J, Cromwell WC, Marais D, Tribble DL, Flaim JD, Crooke ST, Circulation
• Mipomersen, a First-in- Class Apolipoprotein B Synthesis Inhibitor, Lowers Lp(a) in Patients With Homozygous Familial Hypercholesterolemia and High Baseline Lp(a): Res...
  Cromwell W, Santos R, Lachmann R, Gaudet D, Tan JL, Marais D, Raal F, Circulation
• LDL Particle Number is Highly Heterogeneous Among Patients With Type 2 Diabetes Mellitus At LDL Cholesterol Target Goal <100 mg/dL .
  Cromwell WC, Otvos JD, Circulation
• LDL particles, but not LDL cholesterol, are highly elevated in the metabolic syndrome – Results from the Framingham Offspring Study.
  Otvos J, Cromwell W, Shalaurova I, Parise H, Wilson P, Robins S, D’Agostino R, Schaefer E, Circulation
• Effects of simvastatin and atorvastatin on total and fractionated HDL cholesterol.
  Otvos J, Cromwell W, Alexander C, Atherosclerosis, XIIth International Symposium on Atherosclerosis, Stockholm, Sweden
• Fluorescence polarization studies on the ATP binding site of hexokinase.
  Bhatnagar D, Cromwell WC, Roskoski R, Fed Proc
• Thermodynamic and fluorescence studies of the pH dependence of the binding of NAD+ to liver alcohol dehydrogenase.
  Eftink MR, Riggins M, Cromwell W, Biophys J
• Join now to see all

Lectures

• Evaluation and Treatment of Dyslipoproteinemia 
• Role of Lipoprotein Quantification in Evaluation and Management of Atherosclerosis 
• Pathophysiology of Atherosclerosis 
• Lipoprotein Abnormalities in the Metabolic Syndrome 
• Lipoprotein Abnormalities in Type 2 Diabetes Mellitus 
• Join now to see all